Is Interleukin 10 (IL10) Expression in Breast Cancer a Marker of Poor Prognosis?

被引：20
作者：
Bhattacharjee H.K. [1 ]
Bansal V.K. [1 ]
Nepal B. [1 ]
Srivastava S. [2 ]
Dinda A.K. [2 ]
Misra M.C. [1 ]
机构：
[1] Department of Surgical Disciplines, All India Institute of Medical Sciences, New Delhi
[2] Department of Pathology, All India Institute of Medical Sciences, New Delhi
来源：
Indian Journal of Surgical Oncology | 2016年 / 7卷 / 3期
关键词：
Breast cancer; Breast cancer prognosis; Interleukin; 10;
D O I：
10.1007/s13193-016-0512-6
中图分类号：
学科分类号：
摘要：
Interleukin 10 (IL10) is a poor prognostic marker in several cancers. Its role in breast cancer is not well elucidated. The present study is designed to see the expression of IL10 in breast cancer tissue and to evaluate its correlation with the established markers of prognosis. Sixty female patients who underwent surgery for breast cancer were enrolled for the study. Immediately after surgery, 2–5 g of tumour tissue and similar volume of peritumoural normal breast tissue were collected for IL10 assay. IL10 expression was assayed by immunohistochemistry. IL10 expressing tumours and IL10 non expressing tumours were compared. Chi square/Fisher exact test and student’s t test were used to compare the data. p- valueless than 0.05 was considered as statistically significant. Thirty six patients (60 %) of carcinoma breast showed IL 10 expression in tumour tissue as compared to no IL 10 expression in any peritumouralnormal breast tissue (p < 0.01). IL10 expression had statistically significant correlation with locally advanced disease, tumour grade, HER2 + ve tumours and ER-ve, PR-ve, HER2 + ve breast cancer subtypes (p = 0.001, 0.001, 0.001 and 0.01 respectively). No correlation could be found with patient’s age, tumour size, tumour histology and ER and PR status. Correlation of IL10 expressing tumours with several established poor prognostic markers of breast cancer may indicate the possible association of IL10 expression with poor prognosis. Large studies with long term follow up are needed to substantiate the association of IL10 with poor prognosis. © 2016, Indian Association of Surgical Oncology.
引用
收藏
页码：320 / 325
页数：5
相关论文
共 29 条
[1]  
DeSantis C., Ma J., Bryan L., Jemal A., Breast cancer statistics, 2013, CA Cancer J Clin, 64, pp. 52-62, (2014)
[2]  
Hicks D., Turner B., Pathologic diagnosis, immunohistochemistry, multigene assays and breast cancer treatment: progress toward"precision" cancer therapy, Biotech Histochem., 90, pp. 81-92, (2015)
[3]  
Wang J., Ding Q., Shi Y., Et al., The interleukin-10-1082 promoter polymorphism and cancer risk: a meta-analysis, Mutagenesis, 27, pp. 305-312, (2012)
[4]  
Lippitz B.E., Cytokine patterns in patients with cancer: a systematic review, Lancet Oncol, 14, pp. e218-e228, (2013)
[5]  
Hamidullah, Changkija B., Konwar R., Role of interleukin-10 in breast cancer, Breast Cancer Res Treat, 133, pp. 11-21, (2012)
[6]  
Mocellin S., Marincola F., Rossi C.R., Nitti D., Lise M., The multifaceted relationship between IL10 and adaptive immunity: putting together the pieces of a puzzle, Cytokine Growth Factor Rev, 15, pp. 61-76, (2004)
[7]  
Huang S., Ullrich S.E., Bar-Eli M., Regulation of tumor growth and metastasis by interleukin-10: the melanoma experience, J Interf Cytokine Res, 19, pp. 697-703, (1999)
[8]  
Venetsanakos E., Beckman I., Bradley J., Skinner J.M., High incidence of interleukin 10 mRNA but not interleukin 2 mRNA detected in human breast tumours, Br J Cancer, 75, pp. 1826-1830, (1997)
[9]  
Llanes-Fernandez L., Alvarez-Goyanes R.I., Arango-Prado Mdel C., Et al., Relationship between IL-10 and tumor markers in breast cancer patients, Breast, 15, pp. 482-489, (2006)
[10]  
Chavey C., Bibeau F., Gourgou-Bourgade S., Et al., Oestrogen receptor negative breast cancers exhibit high cytokine content, Breast Cancer Res, 9, (2007)
123